MedTrace Logo

PARPi and Ovarian Cancer Survival

NCT06838429 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 6000

Last updated 2025-02-20

No results posted yet for this study

Summary

With the widespread use of PARP inhibitors (PARPi) as maintenance therapy in ovarian cancer, there is still a lack of real-world data from large samples regarding their impact on survival outcomes in advanced and recurrent ovarian cancer. This study aims to conduct a pragmatic cohort study to evaluate the impact of first-line and second-line maintenance treatment with PARPi on survival rates in patients with advanced and recurrent ovarian cancer. The genetic status, different PARPi drugs, and the use of anti-angiogenic inhibitor maintenance therapy or not is used as confounding factors.

Conditions

  • Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum
  • PARP Inhibitor

Sponsors & Collaborators

  • Institute for Ovarian Cancer, Fudan University; Department of Gynecologic Oncology, Cancer Center, Fudan University Zhongshan Hospital, Shanghai, China

    collaborator UNKNOWN

  • Department of Gynecologic Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China

    collaborator UNKNOWN

  • Department of Gynecologic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Sun Yat-sen University

    collaborator UNKNOWN

  • Department of Gynecologic Oncology, Fudan University Cancer Hospital, Shanghai, China

    collaborator UNKNOWN

  • Shanghai Gynecologic Oncology Group

    lead OTHER_GOV

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-31
Primary Completion
2026-03-31
Completion
2026-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06838429 on ClinicalTrials.gov